Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Stock Short Interest Jumps 74.6%

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totaling 7,209 shares, a growth of 74.6% from the September 15th total of 4,130 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average trading volume of 7,501 shares, the short-interest ratio is currently 1.0 days.

Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF

A hedge fund recently bought a new stake in Fidelity Disruptive Medicine ETF stock. Citadel Advisors LLC acquired a new position in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,896 shares of the company’s stock, valued at approximately $282,000. Citadel Advisors LLC owned 0.62% of Fidelity Disruptive Medicine ETF as of its most recent SEC filing.

Fidelity Disruptive Medicine ETF Stock Down 3.1%

FMED stock traded down $0.97 during trading on Friday, reaching $30.27. 17,547 shares of the company’s stock were exchanged, compared to its average volume of 10,454. Fidelity Disruptive Medicine ETF has a 1-year low of $23.48 and a 1-year high of $32.99. The firm has a market cap of $48.42 million, a PE ratio of 41.33 and a beta of 0.76. The company’s fifty day moving average price is $31.51 and its 200-day moving average price is $28.17.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.